Inhibrx Biosciences, Inc. Common Stock When Issued
INXBV
NASDAQ13.92
USD
-2.07
- -
Inhibrx Biosciences, Inc. Common Stock When Issued
INXBV
(NASDAQ)
Recent
price
13.92
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing optimized biologic therapeutics for individuals facing life-threatening conditions. The company emerged in May 2024 as a distinct publicly traded entity, spun off from the original Inhibrx, Inc. immediately prior to the acquisition of the former parent company's INBRX-101 program by Sanofi. This strategic separation provided Inhibrx Biosciences with its own corporate infrastructure and a focused pipeline of novel drug candidates, supported by $200 million in cash from Sanofi. Leveraging a proprietary single-domain antibody platform and advanced modular protein engineering techniques, Inhibrx Biosciences aims to create differentiated treatments. Its primary clinical programs include ozekibart (INBRX-109) and INBRX-106. Ozekibart is a tetravalent death receptor 5 (DR5) agonist, engineered to selectively induce programmed cell death in tumors, currently in Phase 2 trials for unresectable or metastatic conventional chondrosarcoma, with additional investigations in Ewing sarcoma and colorectal cancer. INBRX-106, a hexavalent OX40 agonist, is designed to enhance T-cell activation and robust antitumor responses across various solid tumors, including non-small cell lung cancer, melanoma, and head and neck squamous cell carcinoma. The company anticipates key data readouts for these programs in 2025. As of its latest reports, Inhibrx Biosciences maintains a solid financial foundation with over $200 million in cash to advance its innovative oncology pipeline.